Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Acute Myelogenous Leukemia
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Mylotarg
re-induction treatment of CD33-positive AML adult patients in first relapse who are not candidates for other intensive re-induction chemotherapy regimens (e.g. high-dose Ara-C) and meet at least one of the following criteria: duration of first remission 60 years.
Mylotarg
Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).
Vaccines, Pneumococcal
Diabetes Mellitus
Renal Transplantation
Major Depressive Disorder
Complicated Intra-abdominal Infections